Oligonucleotide replacement for di-tagged and directional libraries

1. A tagmentation method comprising the steps of:

(a) providing target nucleic acids;

(b) providing a plurality of transposomes, wherein a transposome of the plurality of transposomes comprises one or two transposase end sequences selected from the group consisting of:

(SEQ ID NO: 1)

MRWTGTGHWKAVGARACAV

and

(SEQ ID NO: 2)

NSHBGHSHDDRNGAKACAN,

but excluding

(SEQ ID NO: 3)

AGATGTGTATAAGAGACAG;

and

(c) allowing the plurality of transposomes to fragment the target nucleic acids and tag at least one transposase end sequence to the ends of the fragments, thereby generating a library of tagged fragments.

2. The method of claim 1 , wherein the transposase end sequences comprise two SEQ ID NO:1 or two SEQ ID NO:2 or one SEQ ID NO:1 and one SEQ ID NO:2.

3. The method of claim 1 , comprising replacing a nontransferred strand of the transposome with a replacement oligonucleotide in the tagged fragments.

4. The method of claim 3 , comprising ligating the replacement oligonucleotide to the ends of the fragments.

5. The method of claim 1 , wherein the target nucleic acids are double-stranded.

6. The method of claim 5 , wherein one strand of the double-stranded target nucleic acids is chemically modified.

7. The method of claim 6 , wherein the chemical modification is conversion of cytosines to uracils.

8. The method of claim 1 , wherein at least one transposase end sequence of the transposome further comprises a tag sequence.

9. The method of claim 8 , wherein the tag sequence comprises one or more barcodes, one or more primer sites, one or more affinity tags, or one or more reporter moieties, or any combination thereof.

10. The method of claim 8 , wherein the tag sequence of the at least one transposase end sequence comprises a sequence that is different relative to other tag sequences in the plurality of transposomes.

11. The method of claim 1 , wherein at least one transposase end sequence is:

(SEQ ID NO: 5)

CGTTGTGTGGACGAGACAG.

12. The method of claim 1 , wherein at least one transposase end sequence is selected from the group consisting of:

(SEQ ID NO: 4)

CGTTGTGTGGACGAGACAC,

(SEQ ID NO: 6)

AGATGTGCATATGATACAG,

(SEQ ID NO: 22)

TGACGCGGGTAAGAGACAA,

(SEQ ID NO: 23)

GGATGCGATGAGGAGACAA,

(SEQ ID NO: 24)

ACATGACCAAGAGAGACAG,

(SEQ ID NO: 25)

AGCGGTGAATAAGAGACAA,

(SEQ ID NO: 26)

AGCGGTGAATAAGAGACAG,

and

(SEQ ID NO: 27)

ACATGAGTATAAGAGACAA.

13. The method of claim 1 , wherein the transposome comprises two transposase end sequences, wherein the two transposase end sequences comprise a transferred strand and a non-transferred strand, and wherein the non-transferred strand comprises:

(SEQ ID NO: 20)

BTGTYTCBTN1-10

or

(SEQ ID NO: 21)

NTGTMTCNTN0-10.

14. The method of claim 1 , wherein at least one transposase end sequence of the transposome comprise a non-transferred strand selected from the group consisting of: SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.

15. The method of claim 1 , wherein the transposome comprises a Tn5 Mu transposase.

16. The method of claim 1 , wherein the transposome comprises a hyperactive Tn5 transposase.